NCT06310993Not yet recruiting
Exercise to Boost Immunity in Advanced Cancer
Exercise to Boost Immunity in Advanced Cancer: Feasibility of Combined Aerobic Exercise and Resistance Training for Patients with Advanced Mesothelioma and Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 28 Feb 2024
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Diseases
- Mesothelioma, Lung cancer, Pancreatic cancer
- NCT number
- NCT06310993
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Sept 2025 to the primary completion date, 1 Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with systemic anti-cancer treatment
- Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma.
Other illness
- More than one primary cancer
- Patients who have progressed on first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.
- No histological or cytological diagnosis of mesothelioma or pancreatic cancer.
Age
- Age below 18 years old
Other
- Uncontrolled brain or bone metastases
- Patients with active co-morbidities that would prevent or limit their participation in the exercise intervention
- ECOG Performance status of 2 or more
- Unable to provide informed consent
Who the study is looking for
- Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.
- Age over 18 years old
- Histological or cytological diagnosis of mesothelioma or pancreatic cancer.
- ECOG Performance status 0-1 (to be assessed by clinician)
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheffield Hallam University Coordinator of this site? Confirm its status | Sheffield | United Kingdom | Unknown status |
| Cancer Research Centre at Weston Park Hospital Coordinator of this site? Confirm its status | Sheffield | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.